Compare
Cocrystal Pharma, Inc. vs Can-Fite BioPharma Ltd. vs Kala Bio, Inc. vs Longeveron Inc.
| Latest fiscal year | Cocrystal Pharma, Inc. COCP | Can-Fite BioPharma Ltd. CANF | Kala Bio, Inc. KALA | Longeveron Inc. LGVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $405.0K | $0 | $1.20M |
| Revenue growth (YoY) | n/a | -39.9% | n/a | -49.9% |
| Gross margin | n/a | n/a | n/a | 67.0% |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$8.83M | -$9.83M | -$26.98M | -$22.70M |
| EPS (Diluted) | -$0.78 | -$5.97 | -$3.31 | -$1.29 |
| Operating cash flow | -$8.19M | -$8.95M | -$31.99M | -$18.64M |
| Free cash flow | -$8.20M | -$8.95M | n/a | -$18.89M |
| Cash & equivalents | $7.03M | $5.53M | $7.56M | $4.66M |
| Total assets | $9.71M | $9.51M | $9.49M | $10.26M |
| Total liabilities | $3.38M | n/a | $2.49M | $4.59M |
| Shareholders' equity | $6.33M | $5.59M | $7.00M | $5.67M |
| Return on year-end equity | -139.5% | -175.8% | -385.6% | -400.1% |
| Shares outstanding | 13.78M | 2.62M | 27.85M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Cocrystal Pharma, Inc. | Can-Fite BioPharma Ltd. | Kala Bio, Inc. | Longeveron Inc. |
|---|---|---|---|---|
| Latest | $2.01M Ended 2020-12-31 | $405.0K Ended 2025-12-31 | $0 Ended 2025-12-31 | $1.20M Ended 2025-12-31 |
| 1 year earlier | $6.56M Ended 2019-12-31 | $674.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $2.39M Ended 2024-12-31 |
| 2 years earlier | n/a | $743.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $709.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $810.0K Ended 2022-12-31 | $3.89M Ended 2022-12-31 | $1.22M Ended 2022-12-31 |
| 4 years earlier | n/a | $853.0K Ended 2021-12-31 | $11.24M Ended 2021-12-31 | $1.31M Ended 2021-12-31 |